{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.2","value":"5896"},{"groupId":"OG001","spread":"32.9","value":"3915"},{"groupId":"OG002","spread":"43.5","value":"3660"},{"groupId":"OG003","spread":"53.2","value":"4990"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"91"}],"units":"Participants"}],"description":"Blood samples were taken predose and at specified times postdose on Days 1-28 to determine the AUCss of Lenvatinib.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Ewing sarcoma received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"OG000","title":"Ewing Sarcoma"},{"description":"Participants with rhabdomyosarcoma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Participants with high grade glioma received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG002","title":"High Grade Glioma"},{"description":"Participants with other solid tumors received lenvatinib 14 mg/m\\^2 QD orally until progressive disease or unacceptable toxicity.","id":"OG003","title":"Other Solid Tumors Excluding Osteosarcoma"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study treatment and had at least one measurable postdose plasma concentration with an adequately documented dosing history were analyzed. Lenvatinib exposures are reported by the four protocol pre-specified cohorts at the time of enrollment (EWS, RMS, HGG, and Other Solid Tumors excluding Osteosarcoma). For the purposes of the analysis, AUCss was reported for participants with \"Other Solid Tumors\" irrespective of tumor type.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (0.5-4 and 6-10 hours post-dose), Cycle 1 Day 15 (pre-dose, 0.5-4, and 6-10 hours post-dose), and Cycle 2 Day 1 (pre-dose and 2-12 hours post-dose). A cycle is 28 days.","title":"Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)","type":"SECONDARY","unitOfMeasure":"ng*hr/ml"}